Table 2.
Three-marker haplotype analysis of ITGAV single-nucleotide polymorphisms (rs10174098, rs3911238, rs3738919) in the Wellcome Trust Case Control Consortium, New Zealand and Oxford sample sets
| rs10174098 | rs3911238 | rs3738919 | Case, number (frequency) | Control, number (frequency) | P value | OR (95% CI) |
|---|---|---|---|---|---|---|
| WTCCC | ||||||
| 1 | 1 | 2 | 866 (0.261) | 1,451 (0.275) | 0.19 | 0.94 (0.85-1.03) |
| 2 | 1 | 1 | 858 (0.259) | 1,382 (0.262) | 0.82 | 0.99 (0.90-1.09) |
| 1 | 2 | 1 | 792 (0.239) | 1,226 (0.232) | 0.43 | 1.04 (0.94-1.16) |
| 1 | 1 | 1 | 524 (0.158) | 741 (0.140) | 0.021 | 1.15 (1.02-1.30) |
| 2 | 1 | 2 | 219 (0.066) | 405 (0.077) | 0.070 | 0.85 (0.72-1.01) |
| New Zealand | ||||||
| 1 | 1 | 2 | 357 (0.244) | 260 (0.263) | 0.29 | 0.90 (0.75~1.09) |
| 2 | 1 | 1 | 364 (0.249) | 240 (0.243) | 0.73 | 1.03 (0.86~1.25) |
| 1 | 2 | 1 | 359 (0.246) | 223 (0.225) | 0.26 | 1.12 (0.92~1.35) |
| 1 | 1 | 1 | 241 (0.165) | 170 (0.172) | 0.60 | 0.95 (0.76~1.17) |
| 2 | 1 | 2 | 110 (0.075) | 73 (0.074) | 0.91 | 1.02 (0.75~1.39) |
| Oxford, UK | ||||||
| 1 | 1 | 2 | 310 (0.256) | 252 (0.253) | 0.80 | 1.03 (0.85-1.24) |
| 2 | 1 | 1 | 306 (0.253) | 262 (0.262) | 0.67 | 0.96 (0.79-1.16) |
| 1 | 2 | 1 | 335 (0.277) | 251 (0.252) | 0.16 | 1.15 (0.95-1.39) |
| 1 | 1 | 1 | 158 (0.130) | 162 (0.162) | 0.04 | 0.78 (0.62-0.99) |
| 2 | 1 | 2 | 78 (0.064) | 57 (0.057) | 0.47 | 1.14 (0.80-1.62) |
Only haplotypes with frequency of at least 0.05 in controls are shown. CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; WTCCC, Wellcome Trust Case Control Consortium.